Novartis strikes $3.2 billion deal with Alteogen as drug delivery patent licences pile up IAM 14:18 Fri, 04 Sep
Novartis deal caps Alteogen’s banner year as ALT-B4 moves into commercial era Korea Biomedical Review 03:21 Thu, 03 Sep
Novartis taps Alteogen’s Alt-B4 for SC drug delivery in $3B deal BioWorld 20:31 Wed, 02 Sep Article paywall
Novartis signs up to $3.2bn Alteogen deal for subcutaneous drug delivery Manufacturing Chemist 16:10 Wed, 02 Sep
Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products PR Newswire (Press Release) 12:06 Wed, 02 Sep
Alteogen signs deal with Novartis worth up to 4.4 trillion won for subcutaneous formulations Korea JoongAng Daily 09:12 Wed, 02 Sep
Alteogen signs deal with Novartis worth up to $3.2 bil. for subcutaneous formulations The Korea Times 08:24 Wed, 02 Sep
Alteogen signs deal with Novartis worth up to 4.4 tln won for subcutaneous formulations Yonhap News Agency 08:02 Wed, 02 Sep
